research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
Search
for
Sort by
Research
330-360 / 1000+ resultsresearch Use of oral contraceptives in the management of acne
Oral contraceptives can help manage acne by reducing androgen levels.
research Mesotherapy with bicalutamide: A new treatment for androgenetic alopecia
Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
research PEO-b-PCL grafted niosomes: The cooperativilty of amphiphilic components and their properties in vitro and in vivo
The new drug delivery systems made with surfactants and block polymers are stable and not toxic.
research Allopregnanolone promotes proliferation and differential gene expression in human glioblastoma cells
Allopregnanolone increases growth and changes gene activity in human brain cancer cells.
research Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist
CB-03-01 is a promising skin cream for treating hormone-related skin problems without causing harmful body-wide effects.
research Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
research Nanocarriers for optimizing the balance between interfollicular permeation and follicular uptake of topically applied clobetasol to minimize adverse effects
Nanocapsules can improve clobetasol delivery to hair follicles, reducing side effects.
research Faculty Opinions recommendation of Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia.
Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.
research A comparative study of Aldactone® and Diane® in the treatment of hirsutism
Aldactone was more effective in reducing hair growth in women with hirsutism than Diane, despite having less impact on hormone levels.
research Neural substrates of the emotional negativity bias as revealed by haemodynamic data
Cyproterone acetate is a safe treatment that causes mild feminizing effects in adolescent trans-girls.
research Polycystic ovary syndrome and estroprogestins
Choosing the right estroprogestin is crucial for effectively managing PCOS symptoms.
research Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Treatments for PCOS aim to reduce androgen levels and improve insulin sensitivity to lower cardiometabolic risk.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research The influence of selected steroid hormones on the physicochemical behaviour of DPPC liposomes
Steroid hormones change the size, charge, and stability of DPPC liposomes.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients
Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
research Letrozole-Assisted Ovulation Induction Combined with Lifestyle Modification in Women with PCOS: A Review
Letrozole with lifestyle changes improves fertility in women with PCOS.
research Family planning 2011: better use of existing methods, new strategies and more informed choices for female contraception
The conclusion is that there is a high demand for new contraceptives that provide both pregnancy prevention and protection against STIs, along with additional health benefits.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Эффективность комбинированных оральных контрацептивов у женщин с синдромом поликистозных яичников
Both finasteride and drospirenone effectively manage PCOS symptoms, but drospirenone is more effective in reducing ovarian volume and androgen levels.
research Cardiometabolic profile of young women with hypoprolactinemia
Low prolactin in young women may increase heart and metabolism risks.
research Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women
Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.
research 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder
High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
research A Phase 1 Study to Investigate the Effects of Cortexolone 17α‐Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity
Clascoterone is safe for the heart, even at high doses.
research 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials
Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
research Identification of Potential Cytochrome p450c 17 Alpha Inhibitors for the Treatment of PCOS via Scaffold Hopping and Fragment-Based De-Novo Drug Design
Potential new drugs for treating PCOS were identified.
research Combinatorial Therapy of Letrozole- and Quercetin-Loaded Spanlastics for Enhanced Cytotoxicity against MCF-7 Breast Cancer Cells
Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
research Contraceptive use in acne
Hormonal contraceptives can help treat acne by affecting sebum production and androgen levels.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.